Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12810915 | 0.95 | EGFR (0.33) | MTNR1AMTNR1BEGFRCDK2MEN1 | |
| SCHEMBL8041506 | 0.92 | USP2 (0.34) | MTNR1AMTNR1BCDK2MEN1KMT2A | |
| SCHEMBL8051632 | 0.92 | MTNR1A (0.41) | MTNR1AMTNR1BEGFRCDK2UTS2R | |
| SCHEMBL12810903 | 0.91 | MTNR1A (0.36) | MTNR1AMTNR1BEGFRCDK2UTS2R | |
| SCHEMBL12811070 | 0.91 | HTT (0.38) | MTNR1AMTNR1BEGFRCDK2ALDH1A1 | |
| SCHEMBL12811046 | 0.89 | MTNR1A (0.33) | MTNR1AMTNR1BCDK2 | |
| SCHEMBL8044295 | 0.89 | USP2 (0.32) | MTNR1AMTNR1B | |
| SCHEMBL8042392 | 0.88 | CDK2 (0.42) | CDK2MEN1KMT2A | |
| SCHEMBL8048113 | 0.83 | MTNR1A (0.41) | MTNR1AMTNR1BCDK2MEN1KMT2A | |
| SCHEMBL12810902 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203440-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-23 | — | — | EP | disclosed |